Partially/mostly legible archive.is link: https://archive.is/Pp4fT https://archive.is/Pp4fT Or, no paywall: https://www.reuters.com/business/healthcare-pharmac

Partially/mostly legible archive.is link: https://archive.is/Pp4fT https://archive.is/Pp4fT Or, no paywall: https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisks-next-gen-obesity-drug-cagrisema-achieves-lower-weight-loss-than-2024-12-20/ https://www.reuters.com/business/healthcare-pharmaceuticals/... > The CagriSema trial showed the drug helped patients cut their weight by 22.7%, below the 25% Novo Nordisk had expected. Contrasted with Lilly's already approved Zepbound (tirzepatide): > Lilly's own obesity injection - sold as Zepbound in the United States - led to an average weight loss of nearly 23% in clinical trials.